Centessa Pharmaceuticals (CNTA) Total Liabilities (2020 - 2026)

Centessa Pharmaceuticals (CNTA) has 7 years of Total Liabilities data on file, last reported at $154.4 million in Q1 2026.

• Quarterly Total Liabilities rose 9.05% year-over-year to $154.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $154.4 million (up 9.05% YoY) and the FY2025 annual result came in at $160.6 million, down 8.34% from the prior year.
• Total Liabilities retreated to $154.4 million in Q1 2026 per CNTA's latest filing, from $160.6 million in the prior quarter.
• Across five years, Total Liabilities topped out at $175.3 million in Q4 2024 and bottomed at $101.0 million in Q2 2022.
• The 5-year median for Total Liabilities is $116.3 million (2023), against an average of $126.3 million.
• Peak annual rise in Total Liabilities reached 136.62% in 2022, while the deepest fall reached 21.69% in 2022.
• Tracing CNTA's Total Liabilities over 5 years: stood at $108.1 million in 2022, then increased by 14.67% to $124.0 million in 2023, then jumped by 41.33% to $175.3 million in 2024, then fell by 8.34% to $160.6 million in 2025, then declined by 3.87% to $154.4 million in 2026.
• Per Business Quant, the three latest CNTA Total Liabilities figures stand at $154.4 million (Q1 2026), $160.6 million (Q4 2025), and $146.7 million (Q3 2025).

Peer Comparison